MedTrace Logo

French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients

NCT05619978 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-11-17

No results posted yet for this study

Summary

A retrospective multi-center cohort study design was used to address the study objectives, using medical records obtained from three clinical centers in France.

Conditions

  • Chronic Myeloid Leukemia

Interventions

OTHER

3L Therapy

Treatments received in 3L were dasatinib, nilotinib, imatinib, ponatinib, bosutinib, and allo-SCT

OTHER

T315I

Patients with chronic myeloid leukemia with T315I mutation

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-03
Primary Completion
2021-10-29
Completion
2021-10-29

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05619978 on ClinicalTrials.gov